Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSLV 132

Next Previous
X
Search
Drug Profile

RSLV 132

Alternative Names: RSLV-132

Latest Information Update: 08 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Washington University
  • Developer Resolve Therapeutics
  • Class Anti-inflammatories; Antihaemorrhagics; Biological proteins; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action B cell inhibitors; Interferon alpha inhibitors; Ribonuclease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sjogren's syndrome
  • Phase II Post acute COVID 19 syndrome; Subarachnoid haemorrhage; Systemic lupus erythematosus

Most Recent Events

  • 01 Sep 2024 Phase-II clinical trials in Sjogren's syndrome in USA (IV) (NCT06440525)
  • 04 Jun 2024 Resolve Therapeutics plans a phase II trial for Sjorgen's syndrome in September 2024 (IV) (NCT06440525)
  • 20 Dec 2023 Phase-II clinical trials in Subarachnoid haemorrhage in Unknown location (Parenteral) before December 2023 (Resolve Therapeutics pipeline, December 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top